Avestha-Cipla to invest Rs.600 crore for biotech unitsIllustrative image – not actual.

Avesta Biotherapeutics & Research (ABRPL), a 50:50 joint venture between Cipla Group Company Meditab Specialities and Bangalore-based Avestha Gengraine Technologies (Avesthagen), plans to invest around Rs.600 crore to create facilities at Bangalore and Hyderabad in three phases to manufacture biotech drugs.

The proposed joint venture is developing eleven biotech drugs, mainly cancer medications. These include biosimilars for cancer (copycat versions of existing biotech drugs). The company is setting up a Rs.150 crore 200 litre manufacturing facility at Bangalore and is likely to be commissioned by June 2008. Another facility will be built at Bangalore within two to three years at an investment of Rs.300 crore and with a capacity of about 2,500 litre.

ABRPL is also planning to set up a larger facility of about 5,000 litre capacity at Shapoorji Pallonji Biotech Park at Hyderabad in the third phase.

← All latest storiesBack to top →